|
| |
BioJournal - PharmaVentures
http://www.bioportfolio.com/cgi-bin/acatalog/PharmaVentures.html
 |
This covers those essential market changing initiatives which make
tomorrow’s drug market different from today’s. Successful deal making has
accurate valuation at its heart. Anything that impacts a drugs ability to
achieve in the future a fair and profitable market price impacts its value
today. The current market is more challenging than ever before. Payer-driven
price negotiation for reimbursement, and cost-containment programmes to
control prescribing, both challenge the traditional pricing model the
industry has used to generate valuable R&D resource to further the search
for innovation and better disease control. |
 |
In a competitive, fast-paced deal making environment, how can you
maintain your market share? If knowledge is power, then you need to look out
for PharmaVentures' new report, The Pharmaceutical Deals of 2006, and gain
the insight you need to make a difference! |
 |
This publication provides an essential grounding in how to use accepted
and reliable methods for valuing pharmaceutical and biotech projects.
Whether you are about to negotiate a licensing deal or need to perform a
rigorous portfolio review, it is vital that you understand both the value of
a project today and how that value can be built over time. |
 |
This new report can provide a framework for your deal making activities
and includes all the information you need to make informed decisions. The
information covers the global deal making arena and provides facts to answer
your questions, such as:
> What are the latest trends in business opportunities?
> What is the most common deal financial structure?> What are the
partnering interests of European biotechnology companies?
> What were the top 10 licensing, M&A or R&D deals in 2004, in order of
reported value? |
 |
This indispensable report allows even the most experienced deal makers
to translate theoretical discussions into reality. It provides many answers
to key questions arising in deal situations including:
> What are the rationales for different deal structures?
> What is the most relevant deal type to use in a particular situation?>
What are the key issues that must be considered for each deal type?
> How do I value these deals?> What do these deals look like in real
life? |
 |
Nanotechnology in Japan is a rapidly growing area with the Japanese
government being one of the biggest financial contributors in the world
(€691 million FY2004). This specialist report provides in depth information
relating to the developments that are occurring within this specialist
field. |
 |
This unique report is a must read for anyone involved in deal making.
Based on over 12 years experience of assisting pharmaceutical and
biotechnology companies worldwide in all aspects of deal making, the report
seeks to demystify the subject of royalty rates, answering key questions
such as:
> What royalty rates are used in pharmaceutical agreements?
> What are the factors that influence royalty rates?> How do I calculate
and determine royalty rates?
> How are other organisations setting their royalty rates? |
 |
Focusing on partnering in the healthcare industry, this new report
provides a practical 'hands on' guide. The report covers key issues ranging
from finding a partner and being the partner of choice, through valuation
and negotiation to termination of partnerships. Complete with industry
anecdotes the report examines:
> What partnering is
> How to find the right partner> The intricacies of the partnering
process
> The approach strategy> Successfully managing the alliance
> What happens when it all goes wrong |
 |
When it comes to the pricing and reimbursement of new drugs, the world
has undergone considerable change. To ensure that new products are
commercially successful it is vital that companies not only assess the
drug's performance characteristics from a regulatory perspective, but also
its clinical and economic performance in a real life healthcare setting.
With the intensity of deal making and licensing activities growing at a fast
rate, it is therefore imperative that these strategic considerations are
incorporated into your business development activities. This report will
provide you with a detailed understanding of how to use the new P&R reality
to gain a competitive advantage for realising the best deals. |
 |
Dedicated to the drug delivery sector, this report offers a concise and
focused means of assessing and benchmarking drug delivery deal making
activity within the past 9 years. It details valuation methodologies and
explores effective deal structuring to ensure maximum returns. It is a
critical report for all those involved in deal making across both the
pharmaceutical and biotechnology sectors. |
 |
Focusing on the hot topic of influenza, this report offers a topical
insight into both the flu virus and the methods being employed to tackle it.
From an investigative angle, the report specifically explores the
pharmaceutical industry's R&D endeavours in combating the virus, affording a
comprehensive insight into key players in the arena. Main areas of focus
covered by the report include: > The virus and its history
> Key industry insight> An analysis of the market
> Summary of influenza-related deals |
 |
During 2005, seven of the top ten licensing or co-development deals (in
terms of total potential value) involved one of the five companies featured
in the Spotlight Reports big pharma series. These reports will be invaluable
to companies that are looking to collaborate with one of these five
companies. By examining equivalent deals in these reports, you will also be
able to benchmark your deal with any potential big pharma partner. |
http://www.bioportfolio.com/cgi-bin/acatalog/sitemap.html
| |
|
